1.
Korean Journal of Nuclear Medicine
;
: 120-122, 2020.
Article
in 0
| WPRIM
| ID: wpr-997469
ABSTRACT
The positron emission tomography (PET) flow tracer 82Rubidium is a known potassium analogue. During our studies oftumor blood flow in prostate cancer, we found that approximately 10% of the patients had high urinary 82Rubidiumactivity. In roughly half of these patients, the increased renal rubidium/potassium excretion was either causing hypokalemiaor explained by Thiazide treatment. In the other half, there was no obvious explanation or clinical consequence ofthe renal rubidium/potassium excretion. This is the first time enhanced renal potassium excretion is visualized on82Rubidium PET/CT.